Darlene Dobkowski, MA

Patients 60 years and older with gastrointestinal cancers who reported inadequate emotional support were more likely to have poorer physical and mental quality of life, although no effect was observed in overall survival.

Patients with unresectable hepatocellular carcinoma, a type of liver cancer, obtained a survival benefit over four years of follow-up with a treatment regimen of Imfinzi and Imjudo.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Findings from a recent study demonstrated that exposure to Agent Orange increased the risk for bladder cancer but did not affect the disease’s aggressiveness.

Patients 65 years and older treated with Venclexta, Imbruvica and Gazyva for CLL had similar rates of progression-free survival compared with those treated with Imbruvica and Gazyva.

Musician Andrew McMahon has made it his mission to spread the message of community and seeking mental health care like therapy for adolescents and young adults with cancer.

The combination of Talzenna and Xtandi was approved for the treatment of adults with HRR gene-mutated metastatic castration-resistant prostate cancer.

Watch Dr. John O. Mascarenhas, from Icahn School of Medicine, discuss novel therapies in myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. Rami Komrokji, from Moffitt Cancer Center, discuss risk stratification and management of myelofibrosis during the CURE® Educated Patient® MPN Summit.

Columvi is the first bispecific antibody that can be administered to patients with relapsed or refractory diffuse large B-cell lymphoma for a defined period of time.

The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has six months to make a decision.

Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy.

Lynparza plus abiraterone was approved by the FDA for the treatment of patients with deleterious or suspected BRCA-mutated metastatic castration-resistant prostate cancer.

The agency accepted a New Drug Application for repotrectinib, a TKI for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Some symptoms of myeloproliferative neoplasms are “pretty broad,” highlighting the importance of open communication with cancer teams to manage the symptoms and improve quality of life.

Women with hormone receptor-positive breast cancer who temporarily interrupted endocrine therapy for pregnancy had a similar recurrence rate to those from a control group, but one expert said that stopping therapy for a short time is still an important decision.

The approval of Posluma will help clinicians determine the extent of disease in men with prostate cancer and possible management options.

States that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.

Patients born outside of the U.S. may have improved liver cancer survival rates compared with U.S.-born patients, although more research is needed to determine what may be driving this effect, research showed.

Many cancer centers and nonprofit organizations offer resources for patients with cancer and their caregivers to see the support they need to navigate diagnosis, treatment and survivorship.

The costs related to a cancer diagnosis go beyond treatment, reflecting the altered participation in the workforce for adolescents and young adults.

The FDA approval of Epkinly also includes a subset of patients with indolent lymphoma-related DLBCL and those with high-grade B-cell lymphoma after two or more systemic therapies.

Tagrisso plus chemotherapy improved progression-free survival in patients with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer, according to high-level results from a phase 3 trial.

Patients with pancreatic cancer are treated with chemotherapy and surgery, depending on the stage, but more options are needed to treat a disease does not often respond to treatment.

Watch Dr. Percy Lee, from City of Hope, discuss radiation advances during the CURE® Educated Patient® Lung Cancer Summit.

One expert discussed the importance of understanding the different stages of pancreatic cancer and why the disease may be often diagnosed in later stages.

Watch Dr. Thomas Waddington, from City of Hope National Medical Center, discuss the past and future of bronchoscopy during the CURE® Educated Patient® Lung Cancer Summit.

The benefit derived from Tyvyt plus chemotherapy was present regardless of whether previously treated patients with EGFR-mutated, non-squamous non-small cell lung cancer also received Byvasda.

Patients with advanced or recurrent endometrial cancer derived a survival benefit from Jemperli plus chemotherapy.

Patients with advanced or recurrent endometrial cancer treated with Keytruda plus chemotherapy had improved progression-free survival compared with chemotherapy alone.